Versant & MPM Back Synthetic Lethality Newco With $68M

Repare Therapeutics Inc., a Boston and Toronto-based cancer biotech, focusing on synthetic lethality, has hit the ground running with a $68m series A round from seasoned venture capitalists.

Synthetic lethality, a term borrowed by cancer researchers from classical genetics to describe when a cancer mutation and a drug combine to trigger a tumor cell’s death, underpins the creation of biotech newco Repare Therapeutics Inc. Raising $68 million in a series A round, co-led by venture capitalists Versant Ventures and MPM Capital, Repare intends to advance its platform and pipeline of novel medicines that target genetically defined weaknesses of cancers. Other investors in the syndicate included FTQ, Celgene Corp.’s Celgene Switzerland LLC affiliate and BDC Ventures.

“The fields of synthetic lethality and DNA repair have a rich, 20‐year history and are poised to deliver impactful new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.